Skip to main content
User Image

Dr. Taghreed Nasser Almanaa _ تغريد ناصر عبدالعزيز المانع

Assistant Professor

Faculty Member

كلية العلوم
Building 5, Floor 3, Office 202
publication
Journal Article
2021

Lipolytic Postbiotic from Lactobacillus paracasei Manages Metabolic Syndrome in Albino Wistar Rats

Sitohy, Ali Osman، Nashwa El-Gazzar،Taghreed N. Almanaa، Abdalla El‐Hadary and Mahmoud . 2021

The current study investigates the capacity of a lipolytic Lactobacillus paracasei postbiotic as a possible regulator for lipid metabolism by targeting metabolic syndrome as a possibly safer anti-obesity and Anti-dyslipidemia agent replacing atorvastatin (ATOR) and other drugs with proven or suspected health hazards. The high DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS [2,2′-azino-bis (3-ethyl benzothiazoline-6-sulphonic acid)] scavenging activity and high activities of antioxidant enzyme such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-px) of the Lactobacillus paracasei postbiotic (cell-free extract), coupled with considerable lipolytic activity, may support its action against metabolic syndrome. Lactobacillus paracasei isolate was obtained from an Egyptian cheese sample, identified and used for preparing the postbiotic. The postbiotic was characterized and administered to high-fat diet (HFD) albino rats (100 and 200 mg kg−1) for nine weeks, as compared to atorvastatin (ATOR; 10 mg kg−1). The postbiotic could correct the disruption in lipid metabolism and antioxidant enzymes in HFD rats more effectively than ATOR. The two levels of the postbiotic (100 and 200 mg kg−1) reduced total serum lipids by 29% and 34% and serum triglyceride by 32–45% of the positive control level, compared to only 25% and 35% in ATOR’s case, respectively. Both ATOR and the postbiotic (200 mg kg−1) equally decreased total serum cholesterol by about 40% and 39%, while equally raising HDL levels by 28% and 30% of the positive control. The postbiotic counteracted HFD-induced body weight increases more effectively than ATOR without affecting liver and kidney functions or liver histopathology, at the optimal dose of each. The postbiotic is a safer substitute for ATOR in treating metabolic syndrome

Volume Number
26
Magazine \ Newspaper
Molecules
Pages
472
more of publication
publications

The antimicrobial agents of silver nanoparticles (AgNPs) have been applied a little while back in diverse therapeutic studies. In this analysis, AgNPs were biosynthesized using an ecologically…

by Rasha El-Mekkawy, Taghreed N. Almanaa, Marwa A. Yassin, Gamal Rabie, Noha Saleh
2021
publications

The current study investigates the capacity of a lipolytic Lactobacillus paracasei postbiotic as a possible regulator for lipid metabolism by targeting metabolic syndrome as a possibly…

by Ali Osman، Nashwa El-Gazzar،Taghreed N. Almanaa، Abdalla El‐Hadary and Mahmoud Sitohy
2021
publications

Based on the untreated biofilm formation in urinary tract infections (UTIs), current study was focused on the inhibition of Pseudomonas aeruginosa (P. aeruginosa) biofilm formation using Nerium…

by N. Almanaa, Naiyf S. Alharbi, Govindan Ramachandran, Chenthis Kanisha Chelliah, Govindan Rajivgandhi, Natesan Manoharan, Shine Kadaikunnan, Jamal M. Khaled, Khalid F. Alanzi Taghreed
2021